Cole DuMond focuses his practice on public and private mergers and acquisitions, joint ventures, activist defense and general corporate matters.
Mr. DuMond’s notable transactions include representing:
- Newcrest in its A$28.8 billion acquisition by Newmont;
- Occidental Petroleum in the $8.8 billion sale of Anadarko’s African assets to Total;
- Global Blood Therapeutics in its $5.4 billion acquisition by Pfizer;
- Altra in its $5 billion acquisition by Regal Rexnord;
- Deutsche Börse in its $2.275 billion acquisition of ISS;
- Disney in the pending combination of its Hulu + Live TV business with Fubo; ESPN’s proposed joint venture with Fox and Warner Bros. Discovery to launch Venu Sports; ESPN’s strategic alliance with PENN Entertainment to launch ESPN BET, and the related issuance to ESPN of warrants to purchase PENN common shares; the sale of a majority stake in Fox TeleColombia & Estudios TeleMexico to ViacomCBS; and general corporate matters;
- Southwest Gas in its proxy fight and settlement agreement with, and its response to an unsolicited tender offer from, Carl Icahn;
- Hasbro in the sale of its eOne film and TV business to Lionsgate;
- IBM in its acquisition of the Adobe Workfront consultancy and its acquisition of application modernization capabilities from Advanced;
- Pitney Bowes in the sale of Borderfree to Global‑e;
- WiseTech Global in its $230 million acquisition of Envase Technologies from Firmament;
- DRI Capital in the acquisition of a synthetic royalty interest in the worldwide sales of sebetralstat and related equity investment in KalVista Pharmaceuticals and the acquisition from Editas Medicine of payment streams based on the Cas9 gene‑editing technology for CASGEVY;
- Fortress Transportation and Infrastructure Investors in the $150 million sale, plus an earn‑out, of a 49.9% interest in Long Ridge Terminal;
- HBO in its acquisition of Ole Communications’ minority stakes in HBO Ole Partners and HBO Brasil Partners;
- Hibu Group in the sale of its U.S. business to H.I.G. Capital; and
- Univision in its sale of a majority stake to Searchlight and ForgeLight.
Mr. DuMond has been recognized by Lawdragon as among the “500 Leading Dealmakers in America” and the “500 X – The Next Generation.”
Mr. DuMond was born in Hartford, Connecticut. He received a B.S. from the Cornell University School of Hotel Administration in 2013 and a J.D. cum laude from the University of Pennsylvania Law School in 2016.
Mr. DuMond joined Cravath in 2016 and was elected a partner in 2023.
Mr. DuMond’s notable transactions include representing:
- Newcrest in its A$28.8 billion acquisition by Newmont;
- Occidental Petroleum in the $8.8 billion sale of Anadarko’s African assets to Total;
- Global Blood Therapeutics in its $5.4 billion acquisition by Pfizer;
- Altra in its $5 billion acquisition by Regal Rexnord;
- Deutsche Börse in its $2.275 billion acquisition of ISS;
- Disney in the pending combination of its Hulu + Live TV business with Fubo; ESPN’s proposed joint venture with Fox and Warner Bros. Discovery to launch Venu Sports; ESPN’s strategic alliance with PENN Entertainment to launch ESPN BET, and the related issuance to ESPN of warrants to purchase PENN common shares; the sale of a majority stake in Fox TeleColombia & Estudios TeleMexico to ViacomCBS; and general corporate matters;
- Southwest Gas in its proxy fight and settlement agreement with, and its response to an unsolicited tender offer from, Carl Icahn;
- Hasbro in the sale of its eOne film and TV business to Lionsgate;
- IBM in its acquisition of the Adobe Workfront consultancy and its acquisition of application modernization capabilities from Advanced;
- Pitney Bowes in the sale of Borderfree to Global‑e;
- WiseTech Global in its $230 million acquisition of Envase Technologies from Firmament;
- DRI Capital in the acquisition of a synthetic royalty interest in the worldwide sales of sebetralstat and related equity investment in KalVista Pharmaceuticals and the acquisition from Editas Medicine of payment streams based on the Cas9 gene‑editing technology for CASGEVY;
- Fortress Transportation and Infrastructure Investors in the $150 million sale, plus an earn‑out, of a 49.9% interest in Long Ridge Terminal;
- HBO in its acquisition of Ole Communications’ minority stakes in HBO Ole Partners and HBO Brasil Partners;
- Hibu Group in the sale of its U.S. business to H.I.G. Capital; and
- Univision in its sale of a majority stake to Searchlight and ForgeLight.
Mr. DuMond has been recognized by Lawdragon as among the “500 Leading Dealmakers in America” and the “500 X – The Next Generation.”
Mr. DuMond was born in Hartford, Connecticut. He received a B.S. from the Cornell University School of Hotel Administration in 2013 and a J.D. cum laude from the University of Pennsylvania Law School in 2016.
Mr. DuMond joined Cravath in 2016 and was elected a partner in 2023.
Education
-
J.D., 2016, University of Pennsylvania Law Schoolcum laude
-
B.S., 2013, Cornell University
Admitted In
- New York
Rankings
Lawdragon
- 500 Leading Dealmakers in America (2024)
- 500 X – The Next Generation (2024)
Deals & Cases
January 06, 2025
Disney’s Combination of its Hulu + Live TV Business with Fubo
On January 6, 2025, The Walt Disney Company (“Disney”) and FuboTV Inc. (“Fubo) announced that they have entered into a definitive agreement for Disney to combine its Hulu + Live TV business with Fubo, forming a combined virtual MVPD company of which Disney will become the majority owner.
Deals & Cases
November 04, 2024
DRI Healthcare Trust’s Acquisition of a Synthetic Royalty Interest in the Worldwide Sales of Sebetralstat and Equity Investment in KalVista Pharmaceuticals
On November 4, 2024, DRI Healthcare Trust (“the Trust”), a global leader in providing financing to advance innovation in the life sciences industry, announced it has acquired a royalty interest in the worldwide net sales of all formulations of sebetralstat, an investigational oral plasma kallikrein inhibitor for the treatment of Hereditary Angioedema, from KalVista Pharmaceuticals ("KalVista") for an aggregate purchase price of up to $179 million, comprised of a $100 million upfront payment, up to $57 million in a sales-based milestone payment and a one-time $22 million optional payment. Additionally, the Trust is making a $5 million investment in KalVista’s common stock in a private placement transaction. Cravath is representing DRI Healthcare Trust in connection with the transaction.
Deals & Cases
October 04, 2024
DRI Healthcare Trust’s Acquisition of Payment Streams Based on the Cas9 Gene‑Editing Technology for CASGEVY®
On October 3, 2024, DRI Healthcare Trust, a global leader in providing financing to advance innovation in the life sciences industry, announced that one of its wholly owned subsidiaries acquired a portion of Editas Medicine, Inc.'s payment rights under a non‑exclusive license of Editas' Cas9 gene‑editing technology for CASGEVY®, the only approved gene‑edited cell therapy for sickle cell disease and transfusion‑dependent beta thalassemia, for an upfront purchase price of $57 million. The transaction entitles DRI Healthcare to specific payments based on a sublicensing agreement between Editas and Vertex Pharmaceuticals Incorporated. The payments include a share of the annual license fees that Vertex pays to Editas, which can range from $5 million to $40 million, including certain sales‑based annual license fee increases, and a portion of a $50 million contingent payment to which Editas is eligible under the Vertex sublicensing agreement. Cravath is representing DRI Healthcare in connection with the transaction.
Deals & Cases
July 09, 2024
Altus Group’s Sale of Property Tax Business to Ryan, LLC
On July 9, 2024, Altus Group Limited (“Altus Group”), a leading provider of asset and fund intelligence for commercial real estate, announced that it has signed a definitive agreement to sell its global Property Tax business to Ryan, LLC (“Ryan”), a leading global tax services and software provider, for total cash consideration of C$700 million. In addition to the definitive agreement, Ryan has also committed to enter a C$15 million Altus Market Insights subscription agreement at the close of the transaction, with an initial three‑year term of C$5 million per year. Cravath is representing Altus Group as U.S. counsel in connection with the transaction.
Deals & Cases
January 25, 2024
IBM’s Acquisition of Application Modernization Capabilities from Advanced
On January 18, 2024, IBM announced it has signed a definitive agreement to acquire application modernization capabilities from Advanced, bringing a combination of talent, tools and knowledge to enhance IBM Consulting’s mainframe application and data modernization services. Cravath is representing IBM in connection with the transaction.
Cole DuMond focuses his practice on public and private mergers and acquisitions, joint ventures, activist defense and general corporate matters.
Mr. DuMond’s notable transactions include representing:
- Newcrest in its A$28.8 billion acquisition by Newmont;
- Occidental Petroleum in the $8.8 billion sale of Anadarko’s African assets to Total;
- Global Blood Therapeutics in its $5.4 billion acquisition by Pfizer;
- Altra in its $5 billion acquisition by Regal Rexnord;
- Deutsche Börse in its $2.275 billion acquisition of ISS;
- Disney in the pending combination of its Hulu + Live TV business with Fubo; ESPN’s proposed joint venture with Fox and Warner Bros. Discovery to launch Venu Sports; ESPN’s strategic alliance with PENN Entertainment to launch ESPN BET, and the related issuance to ESPN of warrants to purchase PENN common shares; the sale of a majority stake in Fox TeleColombia & Estudios TeleMexico to ViacomCBS; and general corporate matters;
- Southwest Gas in its proxy fight and settlement agreement with, and its response to an unsolicited tender offer from, Carl Icahn;
- Hasbro in the sale of its eOne film and TV business to Lionsgate;
- IBM in its acquisition of the Adobe Workfront consultancy and its acquisition of application modernization capabilities from Advanced;
- Pitney Bowes in the sale of Borderfree to Global‑e;
- WiseTech Global in its $230 million acquisition of Envase Technologies from Firmament;
- DRI Capital in the acquisition of a synthetic royalty interest in the worldwide sales of sebetralstat and related equity investment in KalVista Pharmaceuticals and the acquisition from Editas Medicine of payment streams based on the Cas9 gene‑editing technology for CASGEVY;
- Fortress Transportation and Infrastructure Investors in the $150 million sale, plus an earn‑out, of a 49.9% interest in Long Ridge Terminal;
- HBO in its acquisition of Ole Communications’ minority stakes in HBO Ole Partners and HBO Brasil Partners;
- Hibu Group in the sale of its U.S. business to H.I.G. Capital; and
- Univision in its sale of a majority stake to Searchlight and ForgeLight.
Mr. DuMond has been recognized by Lawdragon as among the “500 Leading Dealmakers in America” and the “500 X – The Next Generation.”
Mr. DuMond was born in Hartford, Connecticut. He received a B.S. from the Cornell University School of Hotel Administration in 2013 and a J.D. cum laude from the University of Pennsylvania Law School in 2016.
Mr. DuMond joined Cravath in 2016 and was elected a partner in 2023.
Mr. DuMond’s notable transactions include representing:
- Newcrest in its A$28.8 billion acquisition by Newmont;
- Occidental Petroleum in the $8.8 billion sale of Anadarko’s African assets to Total;
- Global Blood Therapeutics in its $5.4 billion acquisition by Pfizer;
- Altra in its $5 billion acquisition by Regal Rexnord;
- Deutsche Börse in its $2.275 billion acquisition of ISS;
- Disney in the pending combination of its Hulu + Live TV business with Fubo; ESPN’s proposed joint venture with Fox and Warner Bros. Discovery to launch Venu Sports; ESPN’s strategic alliance with PENN Entertainment to launch ESPN BET, and the related issuance to ESPN of warrants to purchase PENN common shares; the sale of a majority stake in Fox TeleColombia & Estudios TeleMexico to ViacomCBS; and general corporate matters;
- Southwest Gas in its proxy fight and settlement agreement with, and its response to an unsolicited tender offer from, Carl Icahn;
- Hasbro in the sale of its eOne film and TV business to Lionsgate;
- IBM in its acquisition of the Adobe Workfront consultancy and its acquisition of application modernization capabilities from Advanced;
- Pitney Bowes in the sale of Borderfree to Global‑e;
- WiseTech Global in its $230 million acquisition of Envase Technologies from Firmament;
- DRI Capital in the acquisition of a synthetic royalty interest in the worldwide sales of sebetralstat and related equity investment in KalVista Pharmaceuticals and the acquisition from Editas Medicine of payment streams based on the Cas9 gene‑editing technology for CASGEVY;
- Fortress Transportation and Infrastructure Investors in the $150 million sale, plus an earn‑out, of a 49.9% interest in Long Ridge Terminal;
- HBO in its acquisition of Ole Communications’ minority stakes in HBO Ole Partners and HBO Brasil Partners;
- Hibu Group in the sale of its U.S. business to H.I.G. Capital; and
- Univision in its sale of a majority stake to Searchlight and ForgeLight.
Mr. DuMond has been recognized by Lawdragon as among the “500 Leading Dealmakers in America” and the “500 X – The Next Generation.”
Mr. DuMond was born in Hartford, Connecticut. He received a B.S. from the Cornell University School of Hotel Administration in 2013 and a J.D. cum laude from the University of Pennsylvania Law School in 2016.
Mr. DuMond joined Cravath in 2016 and was elected a partner in 2023.
Education
-
J.D., 2016, University of Pennsylvania Law Schoolcum laude
-
B.S., 2013, Cornell University
Admitted In
- New York
Rankings
Lawdragon
- 500 Leading Dealmakers in America (2024)
- 500 X – The Next Generation (2024)
Deals & Cases
January 06, 2025
Disney’s Combination of its Hulu + Live TV Business with Fubo
On January 6, 2025, The Walt Disney Company (“Disney”) and FuboTV Inc. (“Fubo) announced that they have entered into a definitive agreement for Disney to combine its Hulu + Live TV business with Fubo, forming a combined virtual MVPD company of which Disney will become the majority owner.
Deals & Cases
November 04, 2024
DRI Healthcare Trust’s Acquisition of a Synthetic Royalty Interest in the Worldwide Sales of Sebetralstat and Equity Investment in KalVista Pharmaceuticals
On November 4, 2024, DRI Healthcare Trust (“the Trust”), a global leader in providing financing to advance innovation in the life sciences industry, announced it has acquired a royalty interest in the worldwide net sales of all formulations of sebetralstat, an investigational oral plasma kallikrein inhibitor for the treatment of Hereditary Angioedema, from KalVista Pharmaceuticals ("KalVista") for an aggregate purchase price of up to $179 million, comprised of a $100 million upfront payment, up to $57 million in a sales-based milestone payment and a one-time $22 million optional payment. Additionally, the Trust is making a $5 million investment in KalVista’s common stock in a private placement transaction. Cravath is representing DRI Healthcare Trust in connection with the transaction.
Deals & Cases
October 04, 2024
DRI Healthcare Trust’s Acquisition of Payment Streams Based on the Cas9 Gene‑Editing Technology for CASGEVY®
On October 3, 2024, DRI Healthcare Trust, a global leader in providing financing to advance innovation in the life sciences industry, announced that one of its wholly owned subsidiaries acquired a portion of Editas Medicine, Inc.'s payment rights under a non‑exclusive license of Editas' Cas9 gene‑editing technology for CASGEVY®, the only approved gene‑edited cell therapy for sickle cell disease and transfusion‑dependent beta thalassemia, for an upfront purchase price of $57 million. The transaction entitles DRI Healthcare to specific payments based on a sublicensing agreement between Editas and Vertex Pharmaceuticals Incorporated. The payments include a share of the annual license fees that Vertex pays to Editas, which can range from $5 million to $40 million, including certain sales‑based annual license fee increases, and a portion of a $50 million contingent payment to which Editas is eligible under the Vertex sublicensing agreement. Cravath is representing DRI Healthcare in connection with the transaction.
Deals & Cases
July 09, 2024
Altus Group’s Sale of Property Tax Business to Ryan, LLC
On July 9, 2024, Altus Group Limited (“Altus Group”), a leading provider of asset and fund intelligence for commercial real estate, announced that it has signed a definitive agreement to sell its global Property Tax business to Ryan, LLC (“Ryan”), a leading global tax services and software provider, for total cash consideration of C$700 million. In addition to the definitive agreement, Ryan has also committed to enter a C$15 million Altus Market Insights subscription agreement at the close of the transaction, with an initial three‑year term of C$5 million per year. Cravath is representing Altus Group as U.S. counsel in connection with the transaction.
Deals & Cases
January 25, 2024
IBM’s Acquisition of Application Modernization Capabilities from Advanced
On January 18, 2024, IBM announced it has signed a definitive agreement to acquire application modernization capabilities from Advanced, bringing a combination of talent, tools and knowledge to enhance IBM Consulting’s mainframe application and data modernization services. Cravath is representing IBM in connection with the transaction.
Cravath Bicentennial
Celebrating 200 years of partnership. In 2019, we celebrated our bicentennial. Our history mirrors that of our nation. Integral to our story is our culture.
Attorney Advertising. ©2025 Cravath, Swaine & Moore LLP.